Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sobi On The Look-Out For Licensing, M&A Opportunities

Executive Summary

Swedish Orphan Biovitrum AB may be in a launch phase with first sales of its long-acting hemophilia products in Europe, but the company is already looking ahead to use its growing commercial capabilities for other products.

You may also be interested in...



SOBI North America Is Shopping For Growth

Affiliate of the Swedish rare disease specialist has a goal to build the North American business to account for 50% of global sales, an effort that will involve organic growth and M&A.

Hemophilia And Rare Diseases Drive European Mid-Pharmas Sobi And Recordati

Sweden’s Swedish Orphan Biovitrum and Italy’s Recordati are looking towards hemophilia and rare diseases to keep up the growth of their businesses, and Q3 results have highlighted the Swedish company in particular as a potential takeover target.

PIPELINE WATCH – Eight Approvals, Five Orphan Designations And One Filing

This week's Pipeline Watch, a snapshot of all the late-stage R&D and regulatory events in the pharma and biotech industries, is now available to view.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC096921

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel